oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184
AstraZeneca R&D, Neuroscience Therapy Area, Södertälje, Sweden.
NVS Department, Karolinska Institute, Karolinska University Hospital Huddinge, Huddinge, Sweden.
AstraZeneca R&D, Neuroscience Therapy Area, Södertälje, Sweden.
PET Centre, Department of Clinical Neuroscience, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
Show others and affiliations
2009 (English)In: European Journal of Nuclear Medicine and Molecular Imaging, ISSN 1619-7070, E-ISSN 1619-7089, Vol. 36, no 11, p. 1859-1863Article in journal (Refereed) Published
Abstract [en]

PURPOSE: Current positron emission tomography (PET) radioligands for detection of Aβ amyloid in Alzheimer's disease (AD) are not ideal for quantification. To improve the signal to noise ratio we have developed the radioligand [11C]AZD2184 and report here the first clinical evaluation.

METHODS: Eight AD patients and four younger control subjects underwent 93-min PET measurements with [11C]AZD2184. A ratio approach using the cerebellum as reference region was applied to determine binding parameters.

RESULTS: Brain uptake of [11C]AZD2184 peaked within 1 min at 3-4% of injected radioactivity. AD patients had high radioactivity in cortical regions while controls had uniformly low radioactivity uptake. Specific binding peaked within 30 min at which time standardized uptake value ratios (SUVR) ranged between 1.19 and 2.57.

CONCLUSION: [11C]AZD2184 is a promising radioligand for detailed mapping of Aβ amyloid depositions in Alzheimer's disease, due to low non-specific binding, high signal to background ratio and reversible binding as evident from early peak equilibrium.

Place, publisher, year, edition, pages
Springer, 2009. Vol. 36, no 11, p. 1859-1863
Keywords [en]
Alzheimer's disease, Imaging, Amyloid, Biomarker, PET, MRI
National Category
Radiology, Nuclear Medicine and Medical Imaging
Identifiers
URN: urn:nbn:se:oru:diva-74158DOI: 10.1007/s00259-009-1182-1ISI: 000270980400016PubMedID: 19495746Scopus ID: 2-s2.0-72149125332OAI: oai:DiVA.org:oru-74158DiVA, id: diva2:1314554
Funder
AstraZenecaAvailable from: 2019-05-09 Created: 2019-05-09 Last updated: 2019-05-29Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records BETA

Freund-Levi, Yvonne

Search in DiVA

By author/editor
Freund-Levi, Yvonne
In the same journal
European Journal of Nuclear Medicine and Molecular Imaging
Radiology, Nuclear Medicine and Medical Imaging

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 36 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf